bekhterevОбозрение психиатрии и медицинской психологии имени В.М.БехтереваV.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY2313-70532713-055XV. M. BEKHTEREV NATIONAL RESEARCH MEDICAL CENTER FOR PSYCHIATRY AND NEUROLOGY OF THE RUSSIAN FEDERATION MINISTRY OF HEALTH10.31363/2313-7053-2024-972bekhterev-989Research ArticleВ ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУGUIDELINES FOR THE PRACTITIONERМетоды коррекции индуцированной антипсихотиками гиперпролактинемии: актуальное состояние проблемы и перспективы развитияMethods of correction of hyperprolactinemia induced by antipsychotics: current state of the problem and development prospectshttps://orcid.org/0000-0001-7036-5927МазоГ. Э.MazoG. E.

Мазо Галина Элевна — доктор медицинских наук, заместитель директора по инновационному научному развитию, главный научный сотрудник, руководитель института трансляционной психиатрии 

Санкт-Петербург

 

Galina E. Mazo

St. Petersburg

galina-mazo@yandex.ruhttps://orcid.org/0000-0003-2526-0530ЯковлеваЯ. В.YakovlevaYa. V.

Яковлева Яна Викторовна — младший научный сотрудник, аспирант отделения социальной нейропсихиатрии 

Санкт-Петербург

Yana V. Yakovleva

St. Petersburg

yanakov97@yandex.ruНациональный медицинский исследовательский центр психиатрии и неврологии им. В.М. БехтереваРоссияV.M. Bekhterev National Medical Research Center for Psychiatry and NeurologyRussian Federation202425062024582107115Copyright © Мазо Г.Э., Яковлева Я.В., 20242024Мазо Г.Э., Яковлева Я.В.Mazo G.E., Yakovleva Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.bekhterevreview.com/jour/article/view/989

Гиперпролактинемия — одно из распространенных нежелательных явлений антипсихотической терапии, так как связано с рядом психических и соматических осложнений. На сегодняшний день существует несколько стратегий коррекции антипсихотик индуцированной гиперпролактинемии, наибольшую доказательную базу из которых имеет добавление к текущей терапии частичного агониста дофамина — арипипразола.

Другие препараты из данной группы, карипразин и брекспипразол, в связи со сходным механизмом действия с арипипразолом относятся к пролактинсберегающим препаратам. Однако, их различия в фармакодинамике могут определять особенности во влиянии на уровень пролактина и привлекают внимание для дальнейшего изучения их пролактинсберегающей активности.

Hyperprolactinemia is one of the common undesirable phenomena of antipsychotic therapy, as it is associated with a number of mental and somatic complications. To date, there are several strategies for the correction of antipsychotics induced hyperprolactinemia, the most evidential basis of which has an addition to the current treatment of partial dopamine agonist — aripiprazole.

Other drugs in this group, cariprazine and brexpiprazole, due to a similar mechanism of action with aripiprazole, belong to prolactin-saving drugs. However, their differences in pharmacodynamics may determine features in prolactin effects and attract attention for further study of their prolactin-saving activity.

гиперпролактинемияпролактинсберегающие антипсихотикиарипипразолкарипразинhyperprolactinemiaprolactin-saving antipsychoticsaripiprazolecariprazineReferencesГоробец Л.Н., Мазо Г.Э. Гиперпролактинемия при использовании антипсихотиков второго поколения: принципы профилактики, диагностики и коррекции. Обозрение психиатрии и медицинской психологии им. В.М. Бехтерева. 2017;1:63–70.Gorobets LN, Mazo GE. Hyperprolactinemia during application of second-generation antipsychotics:the principles of prevention, diagnosis and correction. Obozreniepsihiatriiimedicinskojpsihologiiim. V.M. Bekhtereva. 2017;1:63–70. (In Russ.).Мазо Г.Э., Кибитов А.О. Современные возможности терапевтической коррекции индуцированной антипсихотиками гиперпролактинемии. Современная терапия Психических Расстройств.2020;1:29–36. doi.org/10.21265/PSYPH.2020Mazo GE, Kibitov AO. Modern Possibilities of Therapeutic Correction of AntipsychoticsInduced Hyperprolactinemia. SovremennayaterapiyaPsihicheskihRasstrojstv. 2020;1:29–36. (In Russ.). doi.org/10.21265/PSYPH.2020Мазо Г.Э., Горобец Л.Н. Осложнения нейролептической гиперпролактинемии. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2018;2:104-108.Mazo GE, Gorobets LN. Complications of neuroleptic hyperprolactinaemia. Obozreniepsihiatriiimedicinskojpsihologiiim. V.M. Bekhtereva. 2018;2:104108. (In Russ.). doi.org/10.31363/2313-7053-2018-2-104-108(In Russ.).Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov. Disord. 2009:15(24):129–133.Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov. Disord. 2009:15(24):129–133.Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano Het al. Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J. Clin. Psychiatry. 2010;71:1131-1137.Arakawa R, Okumura M, Ito H, Takano A, Takahashi H, Takano Het al. Positron emission tomography measurement of dopamine D receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J. Clin. Psychiatry. 2010;71:1131-1137.Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encephale. 2014;40:86-94.Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C. Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance. Encephale. 2014;40:86-94.Bolton JM, Morin SN, Majumdar SR et al. Association of mental disorders and relatedmedication use with risk for major osteoporotic fractures. JAMA Psychiatry.2017;74(6):641-648. doi:10.1001/jamapsychiatry.2017.0449.Bolton JM, Morin SN, Majumdar SR et al. Association of mental disorders and relatedmedication use with risk for major osteoporotic fractures. JAMA Psychiatry.2017;74(6):641-648. doi:10.1001/jamapsychiatry.2017.0449.Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. Journal of Clinical Psychiatry.2008;69:4–17.Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. Journal of Clinical Psychiatry.2008;69:4–17.Bymaster FP, CalligaroDO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87-96.Bymaster FP, CalligaroDO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87-96.Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen. Hosp. Psychiatry. 2008;30:378–380.Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen. Hosp. Psychiatry. 2008;30:378–380.Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010;34(8):1495–1499.Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2010;34(8):1495–1499.Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70:1295–1317.Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70:1295–1317.Culpepper L, Vieta E, Kelly DL, Patel MD, Szatmári B, Hankinson A, Earley WR. Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. NeuropsychiatrDisTreat. 2022;18:995-1011. doi:10.2147/NDT.S348143Culpepper L, Vieta E, Kelly DL, Patel MD, Szatmári B, Hankinson A, Earley WR. Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. NeuropsychiatrDisTreat. 2022;18:995-1011. doi:10.2147/NDT.S348143Delitala G, Masala A, Alagna S. Suppression of pimozide-induced prolactin secretion by piridoxine (vitamin B6). Biomedicine. 1977;27:191–192.Delitala G, Masala A, Alagna S. Suppression of pimozide-induced prolactin secretion by piridoxine (vitamin B6). Biomedicine. 1977;27:191–192.di Filippo L, Doga M, Resmini E, Giustina A. Hyperprolactinemia and bone. Pituitary. 2020;23(3):314321. doi:10.1007/s11102-020-01041-3.di Filippo L, Doga M, Resmini E, Giustina A. Hyperprolactinemia and bone. Pituitary. 2020;23(3):314321. doi:10.1007/s11102-020-01041-3.Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixeddose, Phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–1582. doi:10.4088/JCP.15m09997.Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixeddose, Phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015;76(12):e1574–1582. doi:10.4088/JCP.15m09997.Freeman B, Levy W, Gorman JM. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J. Psychiatr. Pract. 2007;13(2):120–124.Freeman B, Levy W, Gorman JM. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J. Psychiatr. Pract. 2007;13(2):120–124.González-Rodríguez A, Labad J, Seeman MV. Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. ProgNeuropsychopharmacolBiolPsychiatry. 2020;101:109941. doi:10.1016/j.pnpbp.2020.109941González-Rodríguez A, Labad J, Seeman MV. Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. ProgNeuropsychopharmacolBiolPsychiatry. 2020;101:109941. doi:10.1016/j.pnpbp.2020.109941Gupta S, Lakshmanan DAM, Khastgir U, Nair R. Management of antipsychotic-induced hyperprolactinaemia. BJPsychAdvances. 2017;23(4):278-286. doi:10.1192/apt.bp.115.014928Gupta S, Lakshmanan DAM, Khastgir U, Nair R. Management of antipsychotic-induced hyperprolactinaemia. BJPsychAdvances. 2017;23(4):278-286. doi:10.1192/apt.bp.115.014928Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925– 935. doi:10.1016/j.neuint.2011.07.002Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925– 935. doi:10.1016/j.neuint.2011.07.002Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N. The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study. Neuropsychiatr. Dis. Treat. 2014;10:1571–1576.Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N. The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study. Neuropsychiatr. Dis. Treat. 2014;10:1571–1576.Henry JF, Sherwin BB. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. BehavNeurosci. 2012;126:73-85.Henry JF, Sherwin BB. Hormones and cognitive functioning during late pregnancy and postpartum: a longitudinal study. BehavNeurosci. 2012;126:73-85.Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology.2011;74:141–147.Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clinical Endocrinology.2011;74:141–147.Huang YL, Peng M, Zhu G. Topiramate in the treatment of antipsychotic-induced hyperprolactinemia. MedHypotheses. 2020;138:109607. doi:10.1016/j.mehy.2020.109607 .Huang YL, Peng M, Zhu G. Topiramate in the treatment of antipsychotic-induced hyperprolactinemia. MedHypotheses. 2020;138:109607. doi:10.1016/j.mehy.2020.109607 .Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Australian & New Zealand Journal of Psychiatry.2011;45:830–837.Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Australian & New Zealand Journal of Psychiatry.2011;45:830–837.Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, Jönsson EG. Side effect burden of antipsychotic drugs in real life — Impact of gender and polypharmacy. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018;82:263271. https://doi.org/https://doi.org/10.1016/j.pnpbp.2017.11.004 .Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, Jönsson EG. Side effect burden of antipsychotic drugs in real life — Impact of gender and polypharmacy. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2018;82:263271. https://doi.org/https://doi.org/10.1016/j.pnpbp.2017.11.004 .Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf. 2010;2:205-211. doi:10.2147/DHPS.S6226Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf. 2010;2:205-211. doi:10.2147/DHPS.S6226Kaida Jiang, Jijun Wang, Stefan Leucht, Chunbo Li, Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis, Schizophrenia Research. 2021;237:20-25. doi.org/10.1016/j.schres.2021.08.013Kaida Jiang, Jijun Wang, Stefan Leucht, Chunbo Li, Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis, Schizophrenia Research. 2021;237:20-25. doi.org/10.1016/j.schres.2021.08.013Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs. 2020;34(5):473-507. doi:10.1007/s40263-020-00718-4.Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs. 2020;34(5):473-507. doi:10.1007/s40263-020-00718-4.Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55–68. https://doi.org/https://doi.org/10.1016/S0306-4530(02)00127-0;Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55–68. https://doi.org/https://doi.org/10.1016/S0306-4530(02)00127-0;Kopecek M, Bares M, Svarc J, Dockery C, Horácek J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett. 2004;25(6):419-422.Kopecek M, Bares M, Svarc J, Dockery C, Horácek J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett. 2004;25(6):419-422.Krysiak R, Kowalcze K, Szkrobka W, Okopien B. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J InternMed. 2016;30:94-98. doi:10.1016/j.ejim.2016.01.015 .Krysiak R, Kowalcze K, Szkrobka W, Okopien B. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J InternMed. 2016;30:94-98. doi:10.1016/j.ejim.2016.01.015 .Labad J, Montalvo I, González-Rodríguez A, García-Rizo C, Crespo-Facorro B, Monreal JA, Palao D. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophr Res. 2020;222:88-96. doi:10.1016/j.schres.2020.04.031.Labad J, Montalvo I, González-Rodríguez A, García-Rizo C, Crespo-Facorro B, Monreal JA, Palao D. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophr Res. 2020;222:88-96. doi:10.1016/j.schres.2020.04.031.Lee BH, Han CS, Kim KH.Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice. 2005;9:29–34.Lee BH, Han CS, Kim KH.Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice. 2005;9:29–34.Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PloS One. 2013;8(8):e70179. doi:10.1371/journal.pone.0070179Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PloS One. 2013;8(8):e70179. doi:10.1371/journal.pone.0070179Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics: a review. Human Psychopharmacology. 2010;25:281–297.Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics: a review. Human Psychopharmacology. 2010;25:281–297.Meng M, Li W, Zhang S, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry. 2015;27(1):4-17. doi:10.11919/j.issn.1002-0829.215014.Meng M, Li W, Zhang S, et al. Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry. 2015;27(1):4-17. doi:10.11919/j.issn.1002-0829.215014.Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87:5001-5007.Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87:5001-5007.Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62:188-193.Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62:188-193.Montejo ÁL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25-34. doi:10.1016/j.yfrne.2017.02.003.21 .Montejo ÁL, Arango C, Bernardo M, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol. 2017;45:25-34. doi:10.1016/j.yfrne.2017.02.003.21 .Mooney S, Leuendorf JE, Hendrickson C, Hellmann H. Vitamin B6: a long known compound of surprising complexity. Molecules.2009;14:329–351. doi:10.3390/molecules14010329 .Mooney S, Leuendorf JE, Hendrickson C, Hellmann H. Vitamin B6: a long known compound of surprising complexity. Molecules.2009;14:329–351. doi:10.3390/molecules14010329 .Naono-Nagatomo K, Naono H, Abe H, et al. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series. Asian J Psychiatr. 2017;25:36-41. doi:10.1016/j.ajp.2016.10.005Naono-Nagatomo K, Naono H, Abe H, et al. Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series. Asian J Psychiatr. 2017;25:36-41. doi:10.1016/j.ajp.2016.10.005Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs.2014;28:421–453.Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs.2014;28:421–453.Pottegård A, Lash TL, Cronin‐Fenton D, Ahern TP, Damkier P. Use of antipsychotics andrisk of breast cancer: a Danish nationwide case–control study. Br J ClinPharmacol.2018;84(9):2152-2161. doi:10.1111/bcp.13661 .Pottegård A, Lash TL, Cronin‐Fenton D, Ahern TP, Damkier P. Use of antipsychotics andrisk of breast cancer: a Danish nationwide case–control study. Br J ClinPharmacol.2018;84(9):2152-2161. doi:10.1111/bcp.13661 .Ranjbar F, Sadeghi‐Bazargani H, Niari Khams P, Arfaie A, Salari A, Farahbakhsh M. Adjunctive treatment with aripiprazole for risperidone‐induced hyperprolactinemia. NeuropsychiatrDisTreat. 2015;11:549‐555 .Ranjbar F, Sadeghi‐Bazargani H, Niari Khams P, Arfaie A, Salari A, Farahbakhsh M. Adjunctive treatment with aripiprazole for risperidone‐induced hyperprolactinemia. NeuropsychiatrDisTreat. 2015;11:549‐555 .Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. J. Neural Transm. 2018;125:1–14. https://doi.org/10.1007/s00702-018-1869-1Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of l-DOPA-induced dyskinesia. J. Neural Transm. 2018;125:1–14. https://doi.org/10.1007/s00702-018-1869-1Reavley A, Fisher AD, Owen D. Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol. 1997;47:343-347.Reavley A, Fisher AD, Owen D. Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol. 1997;47:343-347.Rusgis MM, Alabbasi AY, Nelson LA. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm. 2021;78(10):862871. doi: 10.1093/ajhp/zxab065. PMID: 33954421Rusgis MM, Alabbasi AY, Nelson LA. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option. Am J Health Syst Pharm. 2021;78(10):862871. doi: 10.1093/ajhp/zxab065. PMID: 33954421Sobrinho LG. Emotional aspects of hyperprolactinemia. PsychotherPsychosom. 1998;67:133-139.Sobrinho LG. Emotional aspects of hyperprolactinemia. PsychotherPsychosom. 1998;67:133-139.Stahl SM. Mechanism of action of cariprazine. CNS Spectr.2016;21:123–127.Stahl SM. Mechanism of action of cariprazine. CNS Spectr.2016;21:123–127.Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M. Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of Psychopharmacology. 2015;29:383-389.Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, Iyo M. Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. Journal of Psychopharmacology. 2015;29:383-389.Tandon R1, Halbreich U. The second-generation ‘atypical’ antipsychotics: similar improved efficacy but different neuroendocrine side effects. SendtoPsychoneuroendocrinology. 2003;28(1):1-7.Tandon R1, Halbreich U. The second-generation ‘atypical’ antipsychotics: similar improved efficacy but different neuroendocrine side effects. SendtoPsychoneuroendocrinology. 2003;28(1):1-7.Tasaki M, Yasui-Furukori N, Yokoyama S, Shinozaki M, Sugawara N, Shimoda K. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. NeuropsychopharmacolRep. 2021;41(3):379-384. doi:10.1002/npr2.12190Tasaki M, Yasui-Furukori N, Yokoyama S, Shinozaki M, Sugawara N, Shimoda K. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. NeuropsychopharmacolRep. 2021;41(3):379-384. doi:10.1002/npr2.12190Taylor D, Chithiramohan R, Grewal J, et al. Dopamine partial agonists: a discrete class of antipsychotics. Int J Psychiatry Clin Pract. 2023;27(3):272284. doi:10.1080/13651501.2022.2151473Taylor D, Chithiramohan R, Grewal J, et al. Dopamine partial agonists: a discrete class of antipsychotics. Int J Psychiatry Clin Pract. 2023;27(3):272284. doi:10.1080/13651501.2022.2151473Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. BMJ. 1984;289:1101–1103. https://doi.org/10.1136/bmj.289.6452.1101Turner TH, Cookson JC, Wass JA, Drury PL, Price PA, Besser GM. Psychotic reactions during treatment of pituitary tumours with dopamine agonists. BMJ. 1984;289:1101–1103. https://doi.org/10.1136/bmj.289.6452.1101Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65:57-61.Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry. 2004;65:57-61.Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: a systematic review and metaanalysis. Systematic Reviews. 2012;1:33.Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: a systematic review and metaanalysis. Systematic Reviews. 2012;1:33.Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review. The British Journal of Psychiatry. 2003;182(3):199– 204.Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: selective literature review. The British Journal of Psychiatry. 2003;182(3):199– 204.Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, Hong CH, Seok JH, Park IH, Son SJ, Roh D, Kim BR, Lee BO. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin. Neuropharmacol. 2016;39:288–294. https://doi.org/10.1097/WNF.0000000000000175.Yoon HW, Lee JS, Park SJ, Lee SK, Choi WJ, Kim TY, Hong CH, Seok JH, Park IH, Son SJ, Roh D, Kim BR, Lee BO. Comparing the effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia: a multicenter, open-label, prospective study. Clin. Neuropharmacol. 2016;39:288–294. https://doi.org/10.1097/WNF.0000000000000175.Zheng W, Cai D-B, Yang X-H, et al. Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis. General Psychiatry 2019;32:e100091. doi:10.1136/gpsych-2019-100091Zheng W, Cai D-B, Yang X-H, et al. Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis. General Psychiatry 2019;32:e100091. doi:10.1136/gpsych-2019-100091Zhuo C, Xu Y, Wang H, Fang T, Chen J, Zhou C, Li Q, Liu J, Xu S, Yao C, Yang W, Yang A, Li B, Chen Y, Tian H and Lin C. Safety and Efficacy of HighDose Vitamin B6 as an Adjunctive Treatment for Antipsychotic-Induced Hyperprolactinemia in Male Patients With Treatment-Resistant Schizophrenia. Front. Psychiatry 2021;12:681418. doi:10.3389/fpsyt.2021.681418Zhuo C, Xu Y, Wang H, Fang T, Chen J, Zhou C, Li Q, Liu J, Xu S, Yao C, Yang W, Yang A, Li B, Chen Y, Tian H and Lin C. Safety and Efficacy of HighDose Vitamin B6 as an Adjunctive Treatment for Antipsychotic-Induced Hyperprolactinemia in Male Patients With Treatment-Resistant Schizophrenia. Front. Psychiatry 2021;12:681418. doi:10.3389/fpsyt.2021.681418

The authors declare that there are no conflicts of interest present.